Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 48
Filtrer
3.
4.
Cutis ; 102(1): 63-64, 2018 Jul.
Article de Anglais | MEDLINE | ID: mdl-30138498

RÉSUMÉ

Psoriasis is a chronic autoimmune skin disease that commonly affects the scalp. Psoriatic lesions on the scalp typically result in alopecia, possibly due to a higher proportion of hairs in the catagen and telogen stages. Involvement of the scalp in psoriasis can be problematic for the patient's quality of life as well as the clinician treating the condition. Here, we present an unusual case of scalp psoriasis presenting with increased hair density in the involved area that was resistant to topical steroids.


Sujet(s)
Psoriasis/diagnostic , Dermatoses du cuir chevelu/diagnostic , Hormones corticosurrénaliennes/usage thérapeutique , Maladie de Crohn , Diagnostic différentiel , Poils/anatomopathologie , Humains , Iléite , Mâle , Psoriasis/traitement médicamenteux , Dermatoses du cuir chevelu/traitement médicamenteux , Jeune adulte
5.
Cutis ; 101(1): 57-60, 2018 Jan.
Article de Anglais | MEDLINE | ID: mdl-29529105

RÉSUMÉ

The use of biologic medications has represented a great advancement in the treatment of moderate to severe plaque psoriasis and has improved patients' quality of life. Despite the increasing popularity of biologics, their neurological side effects have been a constant concern. Reports of demyelinating diseases associated with tumor necrosis factor α (TNF-α) inhibitors continue to accumulate. Additionally, efalizumab was withdrawn from the market in 2009 for causing progressive multifocal leukoencephalopathy (PML). These reports highlight the need for dermatologists to inform patients of the risks and promote informed decision-making with patients prior to starting a biologic agent. Dermatologists also need to recognize early manifestations of neurologic side effects. This review provides an overview of the literature on neurologic diseases that have been found to be associated with biologic agents used for plaque psoriasis. Clinical presentations and diagnostic workups of such diseases are given to aid dermatologists in their early diagnosis and referral.


Sujet(s)
Produits biologiques/administration et posologie , Syndromes neurotoxiques/étiologie , Psoriasis/traitement médicamenteux , Produits biologiques/effets indésirables , Biothérapie/effets indésirables , Biothérapie/méthodes , Prise de décision , Dermatologues/organisation et administration , Humains , Syndromes neurotoxiques/physiopathologie , Rôle médical , Psoriasis/anatomopathologie , Qualité de vie , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs
6.
J Dermatolog Treat ; 29(6): 586-592, 2018 Sep.
Article de Anglais | MEDLINE | ID: mdl-29334280

RÉSUMÉ

PURPOSE: To compare and contrast evidence-based CPGs from leading dermatological organizations for the use of tumor necrosis factor inhibitors (TNFi) in psoriasis. MATERIALS AND METHODS: Guidelines from the British National Institute for Health and Care Excellence (NICE), the British Association of Dermatologists (BAD), the American Academy of Dermatology (AAD), the National Psoriasis Foundation (NPF), and the Canadian Dermatology Association (CDA) were reviewed and compared. RESULTS: Various guidelines are similar regarding treatment initiation but have significant differences regarding topics such as continuous versus intermittent therapy, use in erythrodermic and pustular palmoplantar psoriasis and special patient populations. CONCLUSION: TNF inhibitors remain valuable tools in psoriasis therapy, and guidelines for their use may help clinicians use them effectively.


Sujet(s)
Psoriasis/traitement médicamenteux , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs , Anticorps monoclonaux/usage thérapeutique , Canada , Europe , Recommandations comme sujet , Humains , Psoriasis/anatomopathologie , Indice de gravité de la maladie , Facteur de nécrose tumorale alpha/immunologie , Facteur de nécrose tumorale alpha/métabolisme , Royaume-Uni , États-Unis
7.
Skin Appendage Disord ; 2(3-4): 102-108, 2017 Jan.
Article de Anglais | MEDLINE | ID: mdl-28232916

RÉSUMÉ

BACKGROUND: Nail psoriasis is a painful and disfiguring nail disease that often leads to invasive biopsies. Dermoscopy of the hyponychium can be useful in the diagnosis showing twisted coiled vessels. Structural features of nail psoriasis have been described with optical coherence tomography (OCT). OBJECTIVES: To investigate vascular features of nail psoriasis using dynamic OCT. METHODS: This was an observational, prospective, controlled study in which psoriasis patients with psoriatic nail changes and healthy control patients underwent OCT imaging of the distal nail plate and proximal nail fold. Vertical and horizontal OCT images were analyzed to describe structural and vascular features and to quantify blood flow at depth. RESULTS: Sixteen psoriatic nails and 16 control nails were included. Psoriatic nails had significantly increased blood flow in the proximal nail fold at depths of 0.72 mm (p = 0.035) and 0.76 mm (p = 0.027). Nail thickness was significantly greater in psoriatic nails compared to control nails (p = 0.0016). Compared to control nails, psoriatic nails had dilated, disorganized blood vessels superficially in the proximal nail fold. LIMITATIONS: The main limitation of our study is the relatively small sample size. CONCLUSIONS: OCT can identify structural and vascular features specific to nail psoriasis.

11.
Am J Clin Dermatol ; 17(6): 593-600, 2016 Dec.
Article de Anglais | MEDLINE | ID: mdl-27734331

RÉSUMÉ

Malpractice risk is a common source of concern for the practicing physician. Dermatologists experience fewer lawsuits than most other specialists in medicine, but the risk is not negligible. All physicians should familiarize themselves with areas of potential risk and avoid medico-legal pitfalls. We present Part I of a two-part series addressing medico-legal questions common to most practitioners that cause a great deal of anxiety. Part I will focus upon risk management and prevention of future malpractice lawsuits, and Part II deals with suggestions and guidance once a lawsuit occurs. Herein, we discuss the primary sources of malpractice lawsuits delivered against healthcare practitioners including issues with informed consent, patient noncompliance, medical negligence, and inappropriate documentation, including use of electronic medical records. The overall goal is to effectively avoid these common sources of litigation. The risk management strategies discussed in this paper are relevant to the everyday practitioner and may offer physicians some degree of protection from potential liability.


Sujet(s)
Dermatologie/organisation et administration , Consentement libre et éclairé/législation et jurisprudence , Faute professionnelle/législation et jurisprudence , Erreurs médicales/législation et jurisprudence , Observance par le patient , Gestion du risque/méthodes , Dermatologie/législation et jurisprudence , Documentation , Dossiers médicaux électroniques/législation et jurisprudence , Humains , Guides de bonnes pratiques cliniques comme sujet , Télémédecine/législation et jurisprudence , États-Unis
12.
Am J Clin Dermatol ; 17(6): 601-607, 2016 Dec.
Article de Anglais | MEDLINE | ID: mdl-27785707

RÉSUMÉ

Facing a malpractice lawsuit can be a daunting and traumatic experience for healthcare practitioners, with most clinicians naïve to the legal landscape. It is crucial for physicians to know and understand the malpractice system and his or her role once challenged with litigation. We present part II of a two-part series addressing the most common medicolegal questions that cause a great deal of anxiety. Part I focused upon risk-management strategies and prevention of malpractice lawsuits, whereas part II provides helpful suggestions and guidance for the physician who has been served with a lawsuit complaint. Herein, we address the best approach concerning what to do and what not to do after receipt of a legal claim, during the deposition, and during the trial phases. We also discuss routine concerns that may arise during the development of the case, including the personal, financial, and career implications of a malpractice lawsuit and how these can be best managed. The defense strategies discussed in this paper are not a guide separate from legal representation to winning a lawsuit, but may help physicians prepare for and cope with a medical malpractice lawsuit. This article is written from a US perspective, and therefore not all of the statements made herein will be applicable in other countries. Within the USA, medical practitioners must be familiar with their own state and local laws and should consult with their own legal counsel to obtain advice about specific questions.


Sujet(s)
Dermatologues/psychologie , Dermatologie/législation et jurisprudence , Assurance responsabilité civile , Faute professionnelle/législation et jurisprudence , Relations médecin-patient , Dermatologues/économie , Dermatologues/législation et jurisprudence , Documentation , Humains , Relations interprofessionnelles , National practitioner data bank (USA) , Guides de bonnes pratiques cliniques comme sujet , Relations famille-professionnel de santé , États-Unis
13.
Int J Dermatol ; 55(12): 1369-1372, 2016 Dec.
Article de Anglais | MEDLINE | ID: mdl-27650823

RÉSUMÉ

BACKGROUND: Zika virus (ZIKV) is an arbovirus within the Flaviviridae family, the recent spread of which has promoted public concern. METHODS: This study outlines the clinical features, potential for teratogenicity, diagnosis, and treatment of ZIKV infection. RESULTS: Zika virus is transmitted through the bite of an infected Stegomyia (= Aedes) mosquito, blood transfusion, sexual intercourse, and perinatal routes. Infection has been characterized as mildly symptomatic. Symptoms include mild fever, headache, arthralgia, myalgia, non-purulent conjunctivitis, and a pruritic maculopapular rash. It is rarely life-threatening, but both Guillain-Barré syndrome and fetal microcephaly have been reported. ZIKV belongs to the same family as bovine viral diarrhea virus, which causes hydrocephalus and microcephaly in newborn calves, and hepatitis C virus, which can be vertically transmitted in human pregnancies, and hence there remains concern for potential similarities. Diagnostic methods include polymerase chain reaction performed in blood samples during infection, and in urine and saliva. Pregnant women undergo antibody testing for immunoglobulin M. Treatment involves supportive care, and acetaminophen and antihistamines to control symptoms. CONCLUSIONS: Although there was no evidence of the circulation of ZIKV in the Western hemisphere prior to 2014, the global spread of Stegomyia aegypti and increases in urban populations and international travel have fostered its evolution. Adherence to current guidelines for the prevention of ZIKV transmission is especially relevant in regions experiencing ongoing outbreaks. Concern for microcephaly in newborns warrants further investigation into the potential long-term effects of ZIKV infection, especially in relation to reproductive health and mother-fetus transmission.


Sujet(s)
Épidémies de maladies/histoire , Infection par le virus Zika/histoire , Virus Zika , Amériques/épidémiologie , Femelle , Histoire du 20ème siècle , Histoire du 21ème siècle , Humains , Microcéphalie/virologie , Micronésie/épidémiologie , Polynésie/épidémiologie , Grossesse , Infection par le virus Zika/diagnostic , Infection par le virus Zika/épidémiologie , Infection par le virus Zika/thérapie
19.
J Cosmet Dermatol ; 15(4): 559-560, 2016 Dec.
Article de Anglais | MEDLINE | ID: mdl-27329072

RÉSUMÉ

Dermatologists should be aware of the surgical techniques that reduce the level of skin distortion following biopsy procedures. (1) a dilution of lidocaine with bacteriostatic 0.9% sodium chloride and (2) injection of the solution directly into the nevus. The nevus balloons in size and shape and becomes tenser resulting in a change in the skin level permitting for easy shave. Good injection technique of anesthesia may represent a simple, but important means to improve postoperative cosmetic outcomes.


Sujet(s)
Anesthésiques locaux/administration et posologie , Lidocaïne/administration et posologie , Naevus/chirurgie , Tumeurs cutanées/chirurgie , Procédures chirurgicales dermatologiques/méthodes , Humains , Injections intralésionnelles , Chlorure de sodium/administration et posologie
20.
Lasers Med Sci ; 31(9): 1971-1976, 2016 Dec.
Article de Anglais | MEDLINE | ID: mdl-27324019

RÉSUMÉ

Erythroplasia of Queyrat (EOQ) is a squamous cell carcinoma in situ most commonly located on the glans penis or prepuce. EOQ accounts for roughly 10 % of all penile malignancies and may lead to invasive squamous cell carcinoma. Standard therapy includes local excision, partial or total penectomy, cryotherapy, and topical cytotoxic agents. Treatment of EOQ has proven to be challenging due to low response rates and recurrence. In addition, radical procedures can significantly affect sexual function and quality of life. Alternative laser treatments and photodynamic therapy (PDT) offer promising results for treating EOQ. A systemic review of the literature was performed for articles discussing laser and light therapy for EOQ. Among the patients treated with the CO2 laser, 81.4 % of cases had complete remission after one session of treatment. Patients treated with PDT presented with more variable results, where 62.5 % of those treated with methyl aminolevulinate photodynamic therapy (MAL-PDT) achieved complete remission. Aminolevulinic acid (ALA-PDT) treatment showed a similar rate of remission at 58.3 %. One study utilized the Nd:YAG laser, which resulted in a recurrence of the lesion in four of the five patients treated. Of the methods reviewed, the CO2 laser offered the most promising results with a cosmetically excellent prognosis. Further studies with larger power and longer follow-up times are needed to determine the optimal treatment regimen for this penile malignancy.


Sujet(s)
Carcinome épidermoïde/thérapie , Lasers à gaz/usage thérapeutique , Photothérapie de faible intensité/méthodes , Tumeurs du pénis/thérapie , Photothérapie dynamique/méthodes , Acide amino-lévulinique/analogues et dérivés , Carcinome épidermoïde/traitement médicamenteux , Carcinome épidermoïde/radiothérapie , Humains , Lasers à solide/usage thérapeutique , Mâle , Récidive tumorale locale , Tumeurs du pénis/traitement médicamenteux , Tumeurs du pénis/radiothérapie , Photosensibilisants/usage thérapeutique , Qualité de vie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE